Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment.
about
New and emerging disease modifying therapies for multiple sclerosisMonoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesMultiple sclerosis and pregnancy: current considerationsProphylaxis and treatment of anthrax in pregnant womenPregnancy and Inflammatory Bowel DiseaseOvercoming challenges of treating inflammatory bowel disease in pregnancy.Pregnancy, sex and hormonal factors in multiple sclerosis.Multiple sclerosis and pregnancy; What a neurologist may be asked for?Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Pregnancy in multiple sclerosis: a questionnaire study.Multiple sclerosis and pregnancy: maternal considerations.Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up studyExpert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancyDisease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel diseaseSex and gender issues in multiple sclerosis.Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.What do healthcare providers advise women with multiple sclerosis regarding pregnancy?HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn.Female reproductive issues in multiple sclerosis.Multiple sclerosis and pregnancy: therapeutic considerations.Prolactin in multiple sclerosis.Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review.Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Inflammatory bowel disease in women of reproductive age.Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation.Use of Immunomodulators and Biologics Before, During, and After Pregnancy.Disease activity return after natalizumab cessation in multiple sclerosis.Treatment of multiple sclerosis during pregnancy - safety considerations.Managing IBD Therapies in Pregnancy.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Glatiramer acetate during early pregnancy: A prospective cohort study.Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program.Disease activity following pregnancy-related discontinuation of natalizumab in MS.Natalizumab during pregnancy and lactation.
P2860
Q22242305-0120F459-037B-4A78-99E5-FC7A01C21DE7Q26776234-ED7B702F-7826-4FDA-B06F-B116692D2194Q26830133-8C5975C7-6B23-4B5F-AD16-D00A09686A4DQ28383774-8227EE8E-A5B4-4113-897D-2FF39BE384B0Q28392552-241F0680-1EFE-4766-B083-A25833D14540Q30251775-9097B79B-184F-479B-997D-78C2F70CE6A3Q30354175-99338C73-3721-4FFA-AE9A-565B5490E529Q30428993-6363597D-DA37-4A84-851E-48D3DEC8D3DAQ30659100-1537505A-DF3A-413F-9761-96C32E62D6C7Q33717231-C3DF85E8-50DF-46A4-9CE6-E499FA8CB57EQ34639869-D34C0070-72DB-411F-AA61-9E4440D59F43Q36110582-1C2D6E1C-9A2C-48E6-B701-E9EE4C155220Q36298897-B88D3215-9787-4519-8376-50342A0A5373Q36475245-AE187103-30A3-4BCD-8C74-FC383BDAD545Q36748702-6295B0C3-6E46-4F38-BC81-4FBD5EC7EA10Q36989959-88B602ED-41E1-4B06-8914-FC88B5332DF8Q36999743-02B5D330-EEEE-4A6C-91F6-FBF10C287A36Q37547683-89D16D17-33C5-497A-ACEA-51BADD24E4CBQ37623205-1DF27DED-E43B-47DD-8286-212F7390F21DQ37661566-A6602257-776E-4F28-B08B-BC584B1FC93FQ38020355-1EF4A266-47BF-4B9B-9FE7-281B321C259DQ38021743-D24FF2DC-578A-4AA4-9226-C431A2F38367Q38038437-5BA8BFE8-6D19-425D-905A-E306EC7DE828Q38039054-E8418293-DED7-4F08-86E1-118E1BF578D6Q38085336-3591E14E-B367-41B2-8959-EC756136DA23Q38125249-89D1CACB-DB25-4AA1-8A36-5CBCCC9A9467Q38151555-91C03DB9-4635-485C-A27D-869B8CEFE1B7Q38152451-51CD045D-C5CD-439F-A579-C2E82B177B82Q38192051-AD5EFCA5-CEF4-4700-8FDE-77ADD84068E7Q38246990-BB4D4911-7E72-47EE-9440-2FD37EFCD746Q38601306-ECAD37C1-961A-48E7-ACE5-480F4A0F7CEEQ38779091-81912FDB-003F-49C1-B743-31A4BA4030F2Q38883520-D7AF39CC-F6F9-41A1-A66D-D0DD33BB29DEQ38970533-4E915320-662B-4E91-A11B-93933E64EEC2Q39435409-B436A996-D1AA-4545-B099-C0147015AB51Q40120131-097A617A-FD17-493A-BE38-FE7563BC2979Q44106109-31F3AE4F-741C-4F41-B8A9-7C44C3FFF482Q46118227-32FC958E-9F71-417B-A2DB-C6EFB1973EEFQ49590553-980777FF-5529-4B9C-9660-FBEFD9082122Q50248872-73B39A8A-33DA-4371-BF64-D259D8541096
P2860
Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@en
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@nl
type
label
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@en
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@nl
prefLabel
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@en
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@nl
P2093
P2860
P356
P1476
Pregnancy and natalizumab: res ...... during natalizumab treatment.
@en
P2093
Aiden Haghikia
Kerstin Hellwig
P2860
P304
P356
10.1177/1352458511401944
P577
2011-05-25T00:00:00Z